AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER (AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER).
Aminosyn II 4.25% in Dextrose 10% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories to prevent catabolism. The mechanism involves intravenous administration bypassing gastrointestinal tract, directly providing essential and non-essential amino acids for anabolism and energy in the form of glucose.
| Metabolism | Amino acids are metabolized via transamination and deamination pathways, with carbon skeletons entering the citric acid cycle. Dextrose is metabolized via glycolysis and the citric acid cycle. Metabolism occurs primarily in the liver and other tissues. |
| Excretion | Amino acids are metabolized to urea and other nitrogenous wastes; renal excretion of metabolites accounts for >90% of nitrogen elimination, with <5% excreted unchanged in urine. Dextrose is fully metabolized to CO2 and water. |
| Half-life | Not applicable as a fixed agent; amino acids have distribution half-life of 15-30 min; dextrose has elimination half-life of 1.5-2.5 hours depending on metabolic state. |
| Protein binding | Amino acids: minimal (<10%) binding to albumin; dextrose: not bound. |
| Volume of Distribution | Amino acids: Vd ~0.2-0.3 L/kg (total body water); dextrose: Vd ~0.15-0.25 L/kg (extracellular fluid). |
| Bioavailability | Intravenous: 100% as administered. |
| Onset of Action | Intravenous: immediate caloric and nitrogen source upon infusion; protein synthesis begins within 1-2 hours. |
| Duration of Action | Duration is proportional to infusion rate; continuous infusion provides sustained effect. Post-infusion, amino acid levels decline over 1-2 hours. |
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day by central line, providing 4.25% amino acids and 10% dextrose. Infusion rate typically 1-2 mL/min initially, adjusted to provide 1-1.5 g/kg/day of amino acids and 3-4 g/kg/day of dextrose.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 50 mL/min: reduce amino acid component to 0.5-0.8 g/kg/day and monitor serum urea. For GFR < 20 mL/min: consider essential amino acid formulations; avoid unless on dialysis. |
| Liver impairment | Child-Pugh class B or C: reduce amino acid dose to 0.5-0.8 g/kg/day; avoid in severe hepatic encephalopathy. Use branched-chain amino acid enriched solutions if indicated. |
| Pediatric use | Intravenous infusion via central line. Initial dose: 0.5-1 g/kg/day of amino acids, increase by 0.5 g/kg/day to target 2-3 g/kg/day for term infants and 3-4 g/kg/day for preterm. Dextrose component: start at 4-6 mg/kg/min, titrate to maintain euglycemia. |
| Geriatric use | Start at lower end of adult dosing (0.8-1 g/kg/day amino acids). Monitor renal function; adjust for age-related GFR decline. Infuse at slower rate (0.5-1 mL/min) to avoid fluid overload and hyperglycemia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER (AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER).
| Breastfeeding | No data on excretion into breast milk. Components are normal blood constituents. Likely compatible with breastfeeding, but caution is advised for high glucose levels. M/P ratio not established. |
| Teratogenic Risk | Aminosyn II 4.25% in Dextrose 10% is a parenteral nutrition solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. The risk of teratogenicity is likely low given the endogenous nature of amino acids and dextrose, but high doses of dextrose may cause fetal hyperinsulinemia and hypoglycemia. Use only if clearly needed. First trimester: no specific data, but theoretical risk of hyperglycemia. Second and third trimesters: risk of maternal hyperglycemia leading to fetal hyperinsulinemia, macrosomia, and neonatal hypoglycemia. |
■ FDA Black Box Warning
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
| Serious Effects |
["Severe electrolyte disturbances","Severe fluid overload","Severe hyperglycemia","Severe metabolic acidosis","Inborn errors of amino acid metabolism","Hypersensitivity to any component","Severe hepatic failure (with encephalopathy)"]
| Precautions | ["Monitor serum electrolytes, blood glucose, fluid balance, and renal function regularly","Risk of hyperglycemia, especially in patients with diabetes mellitus or glucose intolerance","Risk of volume overload in patients with cardiac or renal insufficiency","Risk of metabolic acidosis","Risk of infection due to intravenous catheter","Hepatic impairment may require adjustment of amino acid dosage"] |
| Food/Dietary | No specific food interactions; however, this product is used as a nutritional source and may replace oral intake. Monitor overall nutritional status and electrolyte balance. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum glucose, electrolytes, and hepatic function. Monitor fetal growth and well-being with ultrasound and non-stress testing as clinically indicated. Assess for signs of fluid overload or infection. |
| Fertility Effects | No human data on effects on fertility. Animal studies not conducted. Nutritional support is generally not expected to impair fertility; rather, malnutrition may impair fertility. |
| Clinical Pearls | This combination product provides 4.25% amino acids and 10% dextrose for peripheral parenteral nutrition. Infuse via central line only due to high osmolarity (~1050 mOsm/L). Monitor serum glucose, electrolytes, and liver function tests. Avoid abrupt discontinuation to prevent rebound hypoglycemia. Use with caution in renal or hepatic impairment. |
| Patient Advice | Do not change the infusion rate without consulting your healthcare provider. · Report any signs of infection at the catheter site, such as redness, swelling, or drainage. · Inform your doctor if you experience nausea, vomiting, or abdominal pain. · This medication is a source of nutrition and may affect your blood sugar; let your doctor know if you have diabetes. |